Are There Any Clinical Benefits to Screening for Late -Onset Gestational Diabetes Mellitus?"
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-45
SponsorIzmir Ataturk Training and Research Hospital
About this trial
This study aims to screen women who have a negative Gestational diabetes mellitus (GDM) result in routine screening tests or who have never had it with the Fasting Blood Glucose Test (FBG) at 32-34 weeks of gestation to diagnose late-onset GDM with routine FBG ≥5.1 mmol/L (92mg/dl) in fasting blood, and to investigate its connection with perinatal and maternal outcomes, hoping to inform about late-stage GDM.
Eligibility criteria
Qualifiers
Gestational Age: Confirmed singleton pregnancy between 32+0 and 34+6 weeks of gestation based on the last menstrual period (LMP) and/or first-trimester crown-rump length (CRL) ultrasound measurement.
Disqualifiers
Multifetal pregnancies (e.g., twins, triplets) Fetal Anomalies Pre-gestational Chronic Diseases Protocol Non-compliance / Loss to Follow-up Preterm Birth / Preterm Labor
Trial design
Treatments tested in this trial
- Not listed
Trial groups
128 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov